apolipoprotein E4

Overview

Apolipoprotein E4 (APOE4) is a protein isoform encoded by the APOE gene, located on chromosome 19, and represents one of three common isoforms of apolipoprotein E (APOE2, APOE3, and APOE4) distinguished by single amino acid substitutions at positions 112 and 158. As the major cholesterol carrier in the central nervous system (CNS), APOE plays a fundamental role in lipid transport, cholesterol homeostasis, and synaptic maintenance across neural tissues. The APOE4 isoform is distinguished from the more common APOE3 variant by the substitution of arginine for cysteine at position 112, a structural change that profoundly alters the protein's receptor-binding properties, lipid affinity, and metabolic behavior. APOE is also expressed in peripheral tissues, including the liver, and participates in systemic lipid metabolism, immune regulation, and vascular biology.

The APOE4 allele is the most significant known genetic risk factor for late-onset Alzheimer's disease (AD), with each inherited copy conferring approximately a two- to three-fold increased risk relative to the neutral APOE3 background. Homozygous APOE4 carriers face up to a 10- to 15-fold elevated risk compared to APOE3 carriers. Beyond Alzheimer's disease, APOE4 has been implicated in a broad spectrum of conditions including cardiovascular disease, neuroinflammation, and age-related ocular degeneration, positioning it as a high-priority therapeutic and biomarker target across multiple disease domains.

Focus of Latest Publications

Recent publications on apolipoprotein E4 (APOE4) have focused primarily on its role in Alzheimer’s disease and on broader cholesterol- and lipid-related biology. In a proteome-wide association study of Alzheimer’s disease, APOE was identified as a candidate gene in the African American analysis, supporting a putative causal relationship through cis regulation of plasma protein abundance. In a separate study of cognitively normal midlife postmenopausal women, APOE4-related differences in memory-based functional neuroimaging outcomes were examined to probe early brain vulnerability in verbal memory systems, reflecting interest in how APOE4 may shape preclinical cognitive and neuroimaging phenotypes.

Several recent papers also linked APOE/APOE4 to cholesterol transport, redox balance, and metabolic reprogramming. A cerebrospinal fluid biomarker study measured reduced, reversibly oxidized, and irreversibly oxidized apoE and found that apoE3/E4 carriers had higher irreversibly oxidized apoE, consistent with reduced buffering capacity. The same work showed that maintaining the reduced monomeric state was associated with improved cholesterol transport efficiency, while shifts toward oxidation reflected altered CNS pathophysiology. Outside the CNS, APOE appeared in multi-omics studies of tumor and metabolic biology: in colorectal cancer, an SPP1+ APOE+ tumor-associated macrophage subset was linked to CYP27A1-mediated 26-hydroxycholesterol metabolism, immunosuppression, and reduced CD8+ T-cell infiltration; in prostate cancer, APOE was identified among key lipid metabolism regulators associated with fatty acid and cholesterol pathways; in thyroid cancer, APOE was included in a 3-gene prognostic model with PRR15 and C3; and in a nanoplastics toxicity study, APOE was among regulators implicated in oxidative stress and disrupted lipid metabolism.

Therapeutic and translational publications emphasized APOE4 as a target for gene editing and precision medicine. A review on CRISPR-based correction of APOE4 described nuclease disruption, base editing, and prime editing as strategies to modify the allele at its genomic source, with particular attention to delivery systems such as nanoparticles and extracellular exosomes. The review highlighted recent exosome-mediated APOE4 editing advances while noting major barriers, especially blood–brain barrier delivery, allele specificity, and long-term genomic safety. Another review discussed gene editing technologies as a way to enhance stem cell therapy for Alzheimer’s disease by targeting APOE4 and other risk factors, aiming to improve disease modeling, neuroinflammation control, and neuroprotection. In dyslipidemia research, APOE polymorphisms were also examined for their impact on statin efficacy and safety, underscoring continued interest in APOE-related variation in lipid-lowering treatment response.

Key Publications

• NEWJul Multi-omics and metabolic flux modeling reveal that macrophage CYP27A1-derived 26-hydroxycholesterol drives immunosuppression and cancer malignancy. (Discover oncology, 2026, PMID 42399552): "We uncover that CYP27A1-mediated 26-hydroxycholesterol metabolism drives the formation of immunosuppressive SPP1+APOE+TAM in CRC."
• NEWJul Alzheimer's disease proteome-wide association study implicates adaptive immunity and identifies risk genes LILRB1 and SIRPA. (Science translational medicine, 2026, PMID 42384774): "Whereas the African American PWAS identified one candidate [apolipoprotein E (APOE)] and multiple suggestive genes, the European American PWAS identified 18 genes with putative causal relationships with AD through cis regulation of plasma protein abundance."
• NEWJul Evidence of APOE4-related brain vulnerabilities in verbal memory systems in midlife women. (Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026, PMID 42363721): "Women carrying the apolipoprotein E4 (APOE4) allele have a greater risk of Alzheimer's disease (AD) from ages 65-75 years compared to men, yet the effects of APOE4 on cognitive and neuroimaging outcomes among midlife women remain poorly understood."
• NEWJun Machine Learning-Based single-cell characterization of lipid metabolic reprogramming in prostate cancer. (Computers in biology and medicine, 2026, PMID 42361409): "Key hub genes HMGCR, MVK, STARD3, FADS1, and APOE were identified as central regulators of fatty acid and cholesterol metabolism."
• NEWJun Deciphering the interplay between cuproptosis and mitochondrial energy metabolism in thyroid cancer: a multi-omics study for molecular subtyping, prognosis, and tumor microenvironment characterization. (Molecular and cellular biochemistry, 2026, PMID 42319714): "A prognostic signature comprising 15 CMEMRGs was refined to a 3-gene model (APOE, PRR15, and C3) using LASSO regression."
• May Cross-Organ Toxicity and Metabolic Responses to Food Chain-Transferred Nanoplastics: Mechanistic Insights from a Multiomics Perspective. (ACS nano, 2026, PMID 42103696): "Additionally, aberrant expression of critical regulators—including CAT, LPL, NQO1, and APOE—was found to drive oxidative stress and disrupt lipid metabolism."
• May Redox status of apolipoprotein E in cerebrospinal fluid: a mechanistically informative biomarker for central nervous system disorders. (Bioscience reports, 2026, PMID 42012510): "Apolipoprotein (apo) E is the major cholesterol carrier in the central nervous system (CNS); however, the clinical relevance of its cysteine-thiol redox status in cerebrospinal fluid (CSF) remains unclear."
• Apr Investigating the Potential of Gene Editing Technologies in Enhancing Stem Cell Therapy for Alzheimer's Disease. (Current aging science, 2026, PMID 41926312): "This review explores the potential of gene editing to target genetic risk factors associated with AD, such as APOE4 (Apolipoprotein E) and TREM2 (Triggering Receptor Expressed on Myeloid Cells 2), and to improve the differentiation and functionality of induced pluripotent stem cells (iPSCs) derived from AD patients."
• Mar Effects of apolipoprotein E and solute carrier organic anion transporter family member 1B1 gene polymorphisms on statin efficacy and safety in dyslipidemic patients. (Pharmacogenetics and genomics, 2026, PMID 41861156): "To investigate the distribution of the apolipoprotein E (ApoE) and solute carrier organic anion transporter family member 1B1 (SLCO1B1) polymorphisms in dyslipidemia patients and their impact on statin efficacy and safety."
• Apr CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic strategies and macromolecular delivery innovations. (International journal of biological macromolecules, 2026, PMID 41812941): "The apolipoprotein E4 (APOE4) allele is the strongest genetic risk factor for late onset AD, with each copy increasing risk approximately two- to three-fold, and homozygous carriers facing up to a 10- to 15-fold higher risk compared to APOE3 carriers."